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Abstract
Background: Overexpression of fibroblast growth factor receptor 1 (FGFR1), found in ≤8% of hormone receptor–
positive (HR+), human epidermal growth factor receptor 2–negative (HER2−) breast cancer cases, is correlated with
decreased overall survival and resistance to endocrine therapy (ET). Dovitinib, a potent FGFR inhibitor, has demonstrated
antitumor activity in heavily pretreated patients with FGFR pathway–amplified breast cancer.
Methods: In this randomized, placebo-controlled phase II trial, we evaluated whether the addition of dovitinib
to fulvestrant would improve outcomes in postmenopausal patients with HR+, HER2− advanced breast cancer
that had progressed during or after prior ET. Patients were stratified by FGF pathway amplification and presence of
visceral disease, and they were randomized 1:1 to receive fulvestrant plus dovitinib or placebo. The primary endpoint
was progression-free survival (PFS).
Results: From 15 May 2012 to 26 November 2014, 97 patients from 36 centers were enrolled. The frequency of
FGF pathway amplification was lower than anticipated, and the study was terminated early owing to slow accrual of
patients with FGF pathway amplification. The median PFS (95% CI) was 5.5 (3.8–14.0) months vs 5.5 (3.5–10.7) months
in the dovitinib vs placebo arms, respectively (HR, 0.68; did not meet predefined efficacy criteria). For the FGF
pathway–amplified subgroup (n = 31), the median PFS (95% CI) was 10.9 (3.5–16.5) months vs 5.5 (3.5–16.4)
months in the dovitinib vs placebo arms, respectively (HR, 0.64; met the predefined superiority criteria). Frequently
reported adverse events in the dovitinib (diarrhea, nausea, vomiting, asthenia, and headache) and placebo (diarrhea,
fatigue, nausea, and asthenia) arms were mostly low grade.
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Conclusions: The safety profile of dovitinib plus fulvestrant was consistent with the known safety profile of
single-agent dovitinib. Dovitinib in combination with fulvestrant showed promising clinical activity in the FGF
pathway–amplified subgroup. However, the data reported herein should be interpreted with caution, given
that fewer PFS events occurred in the FGF pathway–amplified patients than was expected and that an effect
of dovitinib regardless of FGR pathway amplification status cannot be excluded, because the population was
smaller than expected.
Trial registration: ClinicalTrials.gov identifier: NCT01528345. Registered 31 January 2012.
Keywords: Dovitinib, TKI285, Fulvestrant, FGF, FGFR, Breast cancer, Endocrine resistance
Background
Breast cancer is the most common type of cancer and
the leading cause of cancer deaths in women worldwide
[1]. In most countries, 3% to 12% of breast cancers are
advanced or metastatic at diagnosis [2]. Most breast
cancers are hormone receptor–positive (HR+), with 75%
to 83% of breast cancers expressing estrogen receptor
(ER)-α and/or progesterone receptor [3–5]. Likewise,
approximately 86% to 87% of breast cancers are negative
for overexpression of human epidermal growth factor
receptor 2 (HER2−) [6, 7].
Currently, endocrine therapy is recommended as initial
therapy for patients with HR+, HER2− advanced breast
cancer [8, 9]. Aromatase inhibitors are the standard of care
for postmenopausal patients [9]. However, only 20% to 40%
of patients respond to first-line therapy, and approximately
one-half of responders relapse within 8–14 months [10].
Most patients eventually relapse because currently available
treatments are not curative [11]. Second-line endocrine
therapy (e.g., fulvestrant, aromatase inhibitors, tamoxifen) is
recommended following relapse, but the response is
generally short-lived. For example, the duration of
response (DOR) to second-line fulvestrant or exemes-
tane is approximately 3–5 months [12].
Several mechanisms of endocrine therapy resistance
have been described, including activation of receptor
tyrosine kinases (e.g., fibroblast growth factor receptor
[FGFR]) and their downstream signaling pathways (e.g.,
phosphoinositide 3-kinase [PI3K]/Akt/mechanistic target
of rapamycin [mTOR]), as well as activation of the
cyclin-dependent kinases 4 and 6 that regulate cell cycle
progression [13]. Efforts to improve outcomes and
reduce endocrine therapy resistance have led to the
development of combination therapies that included
targeted agents against these resistance pathways. Posi-
tive results from the phase III Breast Cancer Trials of
Oral Everolimus 2 (BOLERO-2) trial led to the approval
of everolimus, an mTOR inhibitor, in combination with
second-line exemestane in postmenopausal women with
HR+, HER2− advanced breast cancer that progressed
during prior nonsteroidal aromatase inhibitor therapy
[14, 15]. Later, positive results from the Palbociclib:
Ongoing Trials in the Management of Breast Cancer
(PALOMA) studies led to the approval of palbociclib (a
cyclin-dependent kinase 4 and 6 inhibitor) as first-line
therapy in combination with letrozole and as second-
line therapy in combination with fulvestrant [16, 17].
Aberrant regulation of fibroblast growth factor (FGF) and
FGFR signaling is associated with tumorigenic activity [18],
an increased risk of developing breast cancer [19–21], and
resistance to endocrine therapy [13]. Amplifications in
FGFR1 and FGFR4 are found in 9% to 10% and 10% of
primary breast cancers overall, respectively [22–25]. FGFR1
amplification is more frequently associated with luminal B
cancer, whereas FGFR4 amplification is more common in
HR+ tumors and a subset of HER2+ tumors [22, 26, 27].
FGFR2 amplification is present in 4% of triple-negative
breast cancers [28]. Overexpression of FGFR family mem-
bers is associated with poor prognosis, including reduced
overall survival (OS), disease-free survival, and relapse-free
survival [24, 29–31]. FGFR overexpression is also associated
with resistance to hormone therapy [26, 32] and chemo-
therapy [33, 34]. Importantly, FGFR1-induced tamoxifen
resistance can be reversed by inhibiting FGFR1 expression
[32]. Aberrant PI3K/Akt/mTOR signaling is also seen in
cells with FGFR1 overexpression and amplification [26],
and response to the PI3K inhibitor alpelisib is reduced in
ER+/PIK3CA-mutant breast cancer cells that overexpress
FGFR1 [35]. Taken together, these results provide rationale
for the investigation of FGFR inhibitors in breast cancer
therapy.
Dovitinib (TKI258), a small-molecule inhibitor of FGFR1,
FGFR2, and FGFR3 and other receptor tyrosine kinases
[36], has shown preclinical activity in FGFR-expressing
breast cancer models in vivo and in vitro [37]. Dovitinib
inhibited cell proliferation in FGFR-amplified cell lines and
showed antitumor activity in FGFR-amplified xenograft
models [38]. In a phase II trial of single-agent dovitinib,
encouraging clinical activity was observed in patients with
HR+, HER2− FGF pathway–amplified breast cancer [38].
FGF pathway amplification status was determined using in
situ hybridization as part of the eligibility criteria (FGFR1
only) and using quantitative polymerase chain reaction
(qPCR) as an exploratory analysis (FGFR1, FGFR2, and
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FGF3). Correlative studies between FGF pathway amplifica-
tion markers and antitumor activity indicated that dovitinib
activity was higher in patients who had FGF pathway
amplification measured by qPCR, particularly in those
who had higher levels of FGFR1 amplification (i.e., at
least six copies of FGFR1) [38]. The combination of
fulvestrant and dovitinib could potentially overcome
resistance to endocrine therapy, thereby reducing the
need for cytotoxic chemotherapy in relapsed patients.
Together, these data and hypotheses prompted the
initiation of this phase II, placebo-controlled trial of
dovitinib plus fulvestrant in postmenopausal patients with
HR+, HER2− locally advanced or metastatic breast cancer.
The primary objective of this study was to determine
the effect of treatment with dovitinib in combination
with fulvestrant vs placebo plus fulvestrant on progression-
free survival (PFS) in postmenopausal patients with HR+,
HER2− breast cancer that had progressed during or after
prior endocrine therapy in all evaluable patients, regardless
of FGF pathway amplification status, and in patients with
FGF pathway amplification (as measured by qPCR using a
cutoff of at least six copies of FGFR1, FGFR2, or FGF3).
The key secondary objective was overall response rate
(ORR). Additional secondary objectives included DOR,
OS, safety, and pharmacokinetics of dovitinib.
Methods
Study design
We conducted a phase II, multicenter, international, ran-
domized, double-blind, placebo-controlled trial (Clinical-
Trials.gov identifier: NCT01528345) designed to evaluate
the efficacy and safety of dovitinib in combination with
fulvestrant in postmenopausal women with HR+, HER2−
locally advanced or metastatic breast cancer who had
evidence of disease progression. Enrolled patients were
randomized in a 1:1 ratio to receive dovitinib plus fulves-
trant or placebo plus fulvestrant, stratified by FGF path-
way amplification status (amplified vs nonamplified) and
presence of visceral disease (yes vs no). All patients re-
ceived fulvestrant 500 mg (intramuscular injection once
every 4 weeks, with an additional dose 2 weeks after the
initial dose) and dovitinib (500 mg) or placebo orally
following a weekly 5 days on and 2 days off schedule
until death, loss to follow-up, disease progression, or
consent withdrawal.
Patients and medications were randomized using auto-
mated systems. At the time of initial screening, enrolled
patients received a patient number, which was used as the
primary identifier for the patient throughout the study. The
interactive response technology provider generated a ran-
domized patient list, using a validated automated system,
by randomly assigning patient numbers to randomization
numbers. Each randomization number was linked to a
treatment arm and a medication number. Patients were
randomized 1:1 to each of the study arms, with 45 FGF
pathway–amplified and 30 FGF pathway–nonamplified
patients planned in each arm. Medications were separately
randomized by the study sponsor using a validated auto-
mated system that randomly assigned medication numbers
to medication packs containing each of the study treat-
ments. In this double-blind study, patients, investigators,
study team members, and anyone involved in the conduct
of the study remained blinded to the identity of the treat-
ment from the time of randomization until database lock.
The study medication and placebo had identical packaging,
labeling, appearance, and administration schedules to con-
ceal the identity of the treatments.
Patients
Eligible patients were postmenopausal women with HR+,
HER2− locally advanced or metastatic breast cancer who
had evidence of disease progression. Progression was
defined as at least one measurable lesion per Response
Evaluation Criteria In Solid Tumors (RECIST) version 1.1
or at least one nonmeasurable lytic or mixed bone lesion in
the absence of measurable disease. Progression could have
occurred during or after prior endocrine therapy, within
12 months of the end of adjuvant endocrine therapy, or
within 1 month of the end of any endocrine therapy for
localized advanced or metastatic breast cancer. Eligible
patients had confirmed postmenopausal status (i.e., aged
≥55 years with ≥1 year of amenorrhea, aged <55 years with
≥1 year of amenorrhea in the absence of ovarian suppres-
sion with an estradiol assay result of <20 pg/ml, or surgical
menopause with bilateral oophorectomy), Eastern Coopera-
tive Oncology Group (ECOG) performance status ≤2, and
available archival or fresh tumor tissue for FGF pathway sta-
tus determination in the primary tumor by the central la-
boratory. FGF pathway amplification was determined by a
designated Clinical Laboratory Improvement Amend-
ments–certified laboratory using a TaqMan PCR assay (Life
Technologies, Carlsbad, CA, USA), as previously described
[38]. Positive amplification for each FGF pathway marker
tested (i.e., FGFR1, FGFR2, or FGF3) was defined as a copy
number ≥6; copy number was quantified by comparison
with a reference gene (human ribonuclease P RNA compo-
nent H1) and calculated using CopyCaller software (ver-
sion 1.1; Applied Biosystems, Foster City, CA, USA).
Samples were considered to be FGF pathway–amplified if
they had positive amplification of FGFR1, FGFR2, and/or
FGF3. Given that the previously defined amplification cutoff
of at least six copies for FGFR1 was associated with higher
sensitivity to dovitinib monotherapy [38], the same cutoff
was used in this combination therapy study. Exclusion cri-
teria included HER2 overexpression (assessed by immuno-
histochemistry), prior therapy with fulvestrant (as a single
agent or in combination with other therapies) or FGFR in-
hibitors, or chemotherapy or more than one line of any
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prior hormone therapy for locally advanced or metastatic
breast cancer. An estimated 1000 patients were expected to
be screened for FGF pathway amplification in order to iden-
tify and randomize a total of 150 patients stratified by FGF
pathway amplification and presence of visceral disease.
Assessments
Radiographic assessments (computed tomography, mag-
netic resonance imaging, or radiography) were performed
at screening, on day 5 of weeks 8 and 16, before fulvestrant
administration every 8 weeks for the remainder of study
treatment, and at the end of treatment (if not assessed
within 8 weeks before visit). Safety assessments were per-
formed continually until 30 days after the last study treat-
ment. No additional tumor assessments were required to
confirm response (complete response [CR] or partial re-
sponse [PR]) outside the protocol-specified 8-week tumor
assessment.
Patients who did not discontinue study treatment owing
to disease progression or death, or who were not lost to
follow-up or did not withdraw consent, were assessed every
8 weeks for disease status, ECOG performance status, and
patient-reported outcomes until the start of new anticancer
therapy, disease progression, death, loss to follow-up, or
consent withdrawal. Survival follow-up was performed
every 3 months until death, loss to follow-up, or consent
withdrawal for patients who discontinued the treatment.
Study endpoints
The coprimary endpoints were PFS in the overall patient
population regardless of FGF pathway amplification
status and PFS in the subgroup of patients with FGF
pathway amplification. PFS was defined as the time from
date of randomization to the date of first radiologically
documented, investigator-assessed disease progression
per RECIST v1.1 or death due to any cause. The key
secondary endpoint was ORR, defined as the percentage
of patients with best overall response of CR or PR. Add-
itional secondary endpoints included DOR, OS, safety,
and pharmacokinetics of dovitinib. Safety analysis, by
treatment arm, was based on the frequency of adverse
events (AEs), summarized by system organ class, severity
(based on the Common Terminology Criteria for Ad-
verse Events version 4.03), type, and relationship to
study treatment.
Analysis sets
The full analysis set, which consisted of all patients who
were randomized and assigned study treatment, was the
primary population for the efficacy endpoint analyses.
The safety set consisted of all randomized patients who
received at least one dose of any compound of the study
treatment (dovitinib plus fulvestrant or placebo plus
fulvestrant).
Data analysis
The primary endpoint, PFS, was evaluated in each of the
treatment arms using three sets of comparisons, following a
Bayesian design: (1) all patients regardless of FGF pathway
amplification status, (2) FGF pathway–amplified, and (3)
FGF pathway–nonamplified (Additional file 1). Patients
who did not have a PFS event at the time of analysis or
who had received further antineoplastic therapy were
censored at the time of the last tumor assessment. Kaplan-
Meier plots were generated by treatment arm for the full
population, FGF pathway–amplified subpopulation, and
FGF pathway–nonamplified subpopulation. The HR of PFS
in the full population was estimated using a Cox propor-
tional hazards model stratified by FGF pathway amplifica-
tion status and presence of visceral disease (yes vs no).
Efficacy of dovitinib plus fulvestrant over placebo
plus fulvestrant was established if the estimated HR
was <0.68 for the full population (i.e., improvement of
approximately 3.0 months in median PFS) or <0.65 for
the FGF pathway–amplified subpopulation (i.e., im-
provement of approximately 3.5 months in median
PFS). Futility criteria in the FGF pathway–nonampli-
fied subpopulation was determined if the posterior
probability (HR >0.81) was >50% (i.e., improvement of
<1.5 months in median PFS). The number of PFS
events needed for the final analysis was calculated by
assuming a 10% prevalence of FGF pathway amplifica-
tion and a median PFS of 6.5 months with fulvestrant
and placebo. To achieve the required number of PFS
events for the final analysis (≥90 in the full population
and ≥50 in the FGF pathway–amplified subgroup,
whichever occurred later), a total of 150 patients had
to be randomized as follows: 75 patients per treatment
arm (45 FGF pathway–amplified and 30 FGF path-
way–nonamplified).
Separate interim analyses were planned for patients
with and without FGF pathway amplifications, owing to
the faster enrollment expected for the FGF pathway–
nonamplified subgroup. The first interim analyses oc-
curred when 36 PFS events had been documented in the
FGF pathway–nonamplified subgroup, and the second
interim analysis occurred when ≥10 (20%) of 50 PFS
events had been documented in the FGF pathway–amp-
lified subgroup. The intent of these interim analyses was
to assess the efficacy or futility of the study treatment. If
the futility criteria were met (HR >0.81 in the first
interim analysis; HR >0.7 in the second interim analysis),
the study could be terminated early by the data moni-
toring committee.
The key secondary endpoint, ORR, was summarized as
a percentage rate with 95% CI. OS was estimated using
Kaplan-Meier analysis for each treatment arm; patients
still alive at the time of analysis were censored at the last
contact date.
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Results
Patient demographics
From 15 May 2012 to 26 November 2014, a total of 97
postmenopausal patients with HR+, HER2− locally ad-
vanced or metastatic breast cancer that had progressed
during or after hormone therapy were enrolled in 36 cen-
ters. The last patient’s last visit was on 3 April 2015. All
patients received fulvestrant; 47 were randomized to re-
ceive dovitinib and 50 were randomized to receive placebo
(Fig. 1). Overall, 31 patients were classified as FGF path-
way amplified (15 in the dovitinib arm vs 16 in the placebo
arm); 725 patients were screened to enroll 31 FGF path-
way–amplified patients. Although the data monitoring
committee recommended continuing the study after 2 in-
terim analyses, it subsequently recommended early ter-
mination of the study on 30 October 2014 due to lower
than anticipated frequency of FGF pathway amplification
and slow enrollment of patients with FGF pathway–ampli-
fied status. A total of 25 patients in each arm were classi-
fied as having visceral disease (53.2% vs 50.0% of patients
in the dovitinib and placebo arms, respectively).
Baseline characteristics, including age, ECOG perform-
ance status, disease characteristics, and type and number
of prior therapies were comparable between the study
arms (Table 1). The median age for all patients was 63
(range 38–82) years; the median weight for all patients
was 66.0 (range 38.0–135.5) kg; and the majority (57.7%)
of patients had an ECOG performance status of 0. For pa-
tients with metastatic disease, the most common
metastatic site was bone (77.3%), followed by lymph nodes
(48.5%) and liver (39.2%). Most patients (76.3%) had been
initially diagnosed ≥24 months before study start. Overall,
48.5% of patients had de novo stage IV disease, which was
balanced between the dovitinib and placebo arms (48.9%
vs 48.8% overall; 19.1% vs 16.0% FGF pathway–amplified;
29.8% vs 32.0% FGF pathway–nonamplified). The majority
of patients relapsed at or within 12 months of the end of
adjuvant treatment with any endocrine therapy (50
[51.5%] of 97 patients), and 48.5% (47 of 97) of patients
progressed at or within 1 month of end of any endocrine
therapy treatment for first-line treatment of metastatic
disease. All patients had received prior antineoplastic ther-
apy, including surgery (100%), hormone therapy (100%),
radiotherapy (77.3%), and chemotherapy (66.0%). Ap-
proximately one-half (49.5%) of patients had received
prior tamoxifen, and most patients had received prior aro-
matase inhibitors, including letrozole (42.3%), anastrozole
(35.1%), and exemestane (17.5%). The majority (62.9%) of




The median (95% CI) PFS for the full population were 5.5
(3.8–14.0) months and 5.5 (3.5–10.7) months in the dovi-
tinib and placebo arms, respectively, with an estimated
HR of 0.68 (95% CI 0.41–1.14) (Fig. 2a), with 30 events in
the dovitinib arm and 34 events in the placebo arm. The
Fig. 1 Consolidated Standards of Reporting Trials (CONSORT) diagram of patient disposition for patients randomized to receive dovitinib plus
fulvestrant or placebo plus fulvestrant. FGF Fibroblast growth factor
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Table 1 Baseline patient demographics and disease characteristics
Baseline parameters Fulvestrant + dovitinib (n = 47) Fulvestrant + placebo (n = 50) All patients (n = 97)
Patient demographics
Median age (range), years 63 (44–82) 63 (38–82) 63 (38–82)
Median weight (range), kg 66.5 (38.0–95.0) 65.0 (41.0–135.5) 66.0 (38.0–135.5)
ECOG performance status, n (%)
0 28 (59.6) 28 (56.0) 56 (57.7)
1 18 (38.8) 20 (40.0) 38 (39.2)
2 1 (2.1) 2 (4.0) 3 (3.1)
FGF pathway amplified, n (%)a
No 32 (68.1) 33 (66.0) 65 (67.0)
Yes 15 (31.9) 17 (34.0) 32 (33.0)
Presence of visceral disease, n (%)b
No 12 (25.5) 20 (40.0) 32 (33.0)
Yes 35 (74.5) 30 (60.0) 65 (67.0)
Disease characteristics, n (%)
Primary site of cancer
Breast 47 (100) 50 (100) 97 (100)
Metastatic site of cancer
Bone 39 (83.0) 36 (72.0) 75 (77.3)
Lymph nodes 21 (44.7) 26 (52.0) 47 (48.5)
Liver 22 (46.8) 16 (32.0) 38 (39.2)
Other 19 (40.4) 8 (16.0) 27 (27.8)
Adrenal 3 (6.4) 3 (6.0) 6 (6.2)
Breast 0 1 (2.0) 1 (1.0)
Time from initial diagnosis of primary site to start of study drug
<6 months 0 0 0
6 to <12 months 2 (4.3) 4 (8.0) 6 (6.2)
12 to <24 months 5 (10.6) 8 (16.0) 13 (13.4)
≥24 months 40 (85.1) 38 (76.0) 78 (80.4)
De novo stage IV 23 (48.9) 24 (48.0) 47 (48.5)
FGF pathway–amplified 9 (19.1) 6 (16.0)
FGF pathway–nonamplified 14 (29.8) 16 (32.0)
Prior therapies, n (%)
Antineoplastic therapyc 47 (100) 50 (100) 97 (100)
Surgery 47 (100) 50 (100) 97 (100)
Hormone therapy 47 (100) 50 (100) 97 (100)
Radiotherapy 37 (78.7) 38 (76.0) 75 (77.3)
Chemotherapy 32 (68.1) 32 (64.0) 64 (66.0)
Therapy type at last treatment
Hormone therapy 43 (91.5) 48 (96.0) 91 (93.8)
Chemotherapy 0 1 (2.0) 1 (1.0)
Other 4 (8.5) 1 (2.0) 5 (5.2)
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estimated HR did not meet the criterion for superior
efficacy of dovitinib vs placebo (i.e., HR <0.68). The
median (95% CI) PFS values were 10.9 (3.5–16.5) months
and 5.5 (3.5–16.4) months in the FGF pathway–amplified
subgroup and 5.5 (3.8–16.8) months and 5.5 (1.9–12.8)
months in the FGF pathway–nonamplified subgroup for
the dovitinib and placebo arms, respectively (Fig. 2b and
c). The HRs (95% CIs) were 0.64 (0.22–1.86) for the FGF
pathway–amplified subgroup and 0.69 (0.38–1.26) for the
FGF pathway–nonamplified subgroup, which was suffi-
cient to meet the efficacy criteria for the FGF pathway–
amplified subgroup (i.e., HR <0.65) and pass the futility
criteria for the FGF pathway–nonamplified subgroup (i.e.,
HR >0.81). Fewer PFS events than expected occurred in
FGF pathway–amplified patients (18 vs planned 50
events); thus, results in that subgroup should be inter-
preted with caution.
Best overall response
The ORRs (95% CIs) per local investigator assessment in
all patients were 27.7% (15.6% to 42.6%) in the dovitinib
arm and 10.0% (3.3% to 21.8%) in the placebo arm
(Table 2). According to FGF pathway amplification
status, the ORRs (95% CIs) for each treatment arm
(dovitinib vs placebo) were 20.0% (4.3% to 48.1%) vs
12.5% (1.6% to 38.3%) in the FGF pathway–amplified
subgroup and 31.3% (16.1% to 50.0%) vs 8.8% (1.9% to
23.7%) in the FGF pathway–nonamplified subgroup. In
an exploratory analysis, we found no correlation between
the FGFR1 copy number and response to dovitinib in
the FGF pathway–amplified subgroup, with the caveat
that the analyzed patient population was small. When
considering only those patients who had measurable
disease at baseline (n = 41 [87.2%] in the dovitinib arm;
n = 39 [78.0%] in the placebo arm), the ORRs (95% CIs)
per local investigator assessment were 31.7% (18.1% to
48.1%) in the dovitinib arm and 12.8% (4.3% to 27.4%) in
the placebo arm.
Time to response and duration of response
In patients who responded, the median (95% CI) time to
first response in the dovitinib arm vs placebo arm was 2.0
(1.5–18.3) months vs 3.7 (1.6–9.1) months in the full
population. Of the 13 patients who responded in the
dovitinib arm, 11 patients (84.6%) responded within the
first 4 months, 1 patient (7.7%) responded between 4 and
<6 months, and 1 patient (7.7%) responded after
18 months of receiving the first dose of study treatment.
Of the five patients who responded in the placebo arm,
three patients (60.0%) responded within the first 4 months,
and two patients (40.0%) responded between 6 and
<12 months of initiating study treatment. The median
(95% CI) values for DOR in the dovitinib arm vs placebo
arm were 13.5 (5.5–16.6) months vs 14.7 (3.3–not estim-
able [NE]) months in the full population, 5.5 (3.2–16.3)
months vs 14.7 (NE–NE) months in the FGF pathway–
amplified subgroup, and 14.8 (5.5–NE) months vs 10.9
(3.3–NE) months in the FGF pathway–nonamplified
Table 1 Baseline patient demographics and disease characteristics (Continued)
Prior hormone therapies, n (%)
Number of prior hormone regimens
1 28 (59.6) 36 (72.0) 64 (66.0)
2 17 (36.2) 13 (26.0) 30 (30.9)
3 2 (4.3) 1 (2.0) 3 (3.1)
Settingd
Adjuvant/neoadjuvant setting 38 (80.9) 37 (74.0) 75 (77.3)
Therapeutic setting 23 (48.9) 24 (48.0) 47 (48.5)
Prevention 4 (8.5) 3 (6.0) 7 (7.2)
Regimen type
Tamoxifen 27 (57.4) 21 (42.0) 48 (49.5)
Letrozole 18 (38.3) 23 (46.0) 41 (42.3)
Anastrozole 16 (34.0) 18 (36.0) 34 (35.1)
Exemestane 8 (17.0) 9 (18.0) 17 (17.5)
Othere 1 (2.1) 4 (8.0) 5 (5.2)
ECOG European Cooperative Oncology Group, FGF Fibroblast growth factor
aDerived from biomarker data and determined by the central laboratory to be positive for gene amplification of fibroblast growth factor receptor 1 (FGFR1),
FGFR2, or FGF3
bBased on electronic case report forms; visceral refers to lung, liver, pleural, or peritoneal involvement
cIncludes patients who had medication, radiotherapy, or surgery
dA patient may have been treated in multiple settings
eOther prior hormone regimens included goserelin (n = 3), toremifene (n = 1), and triptorelin (n = 1)
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subgroup. These data should be interpreted with caution
owing to the small sample size.
Overall survival
The median (95% CI) OS was not reached (18.6 months–
NE) in the dovitinib arm and was 25.9 (18.4–NE) months
in the placebo arm (Fig. 3).
Safety
All patients received at least one dose of dovitinib or
placebo and have discontinued study treatment (see Fig. 1).
Of note, on the basis of the intention-to-treat principle,
one patient with FGF pathway amplification who was
misclassified as nonamplified at randomization remained
in the nonamplified group in all analyses. The reasons for
discontinuation in the dovitinib vs placebo arms were
progressive disease (55.3% vs 80.0%), AEs (21.3% vs 2.0%),
patient or guardian decision (10.6% vs 0%), termination by
sponsor (8.5% vs 16.0%), death (2.1% vs 2.0%), and nonad-
herence to study treatment (2.1% vs 0%). The majority of
patients who received dovitinib required at least one dose
reduction or interruption (74.5% vs 26.0% for those who
Fig. 2 Investigator-assessed PFS by treatment for all patients (a), FGF pathway–amplified patients (b), and FGF pathway–nonamplified patients (c).
FGF Fibroblast growth factor, PFS Progression-free survival
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Table 2 Best overall response per local investigator review in the full analysis set
Dovitinib + fulvestrant (n = 47) Placebo + fulvestrant (n = 50)
All patients
Best overall response, n (%)
CR 1 (2.1) 1 (2.0)
PR 12 (25.5) 4 (8.0)
SD 18 (38.3) 16 (32.0)
PD 4 (8.5) 13 (26.0)
Non-CR/non-PD 6 (12.8) 9 (18.0)
Unknown 6 (12.8) 7 (14.0)
Overall response rate (CR + PR)
[95% CI], n (%)
13 (27.7) [15.6–42.6] 5 (10.0) [3.3–21.8]
Median time to first response
[95% CI], months
2.0 [1.5–18.8] 3.7 [1.6–9.1]
Median duration of response
[95% CI], months
13.5 [5.5–16.6] 14.7 [3.3–NE]










Best overall response, n (%)
CR 0 1 (3.1) 1 (6.3) 0
PR 3 (20.0) 9 (28.1) 1 (6.3) 3 (8.8)
SD 7 (46.7) 11 (34.4) 4 (25.0) 12 (35.3)
PD 1 (6.7) 3 (9.4) 2 (12.5) 11 (32.4)
Non-CR/non-PD 2 (13.3) 4 (12.5) 6 (37.5) 3 (8.8)
Unknown 2 (13.3) 4 (12.5) 2 (12.5) 5 (14.7)
Overall response rate (CR + PR)
[95% CI], n (%)
3 (20.0) [4.3–48.1] 10 (31.3) [16.1–50.0] 2 (12.5) [1.6–38.3] 3 (8.8) [1.9–23.7]
Median duration of response
[95% CI], months
5.5 [3.2–16.3] 14.8 [5.5–NE] 14.7 [NE–NE] 10.9 [3.3–NE]
Abbreviations: CR Complete response, FGF Fibroblast growth factor, NE Not estimable, PD Progressive disease, PR Partial response, SD Stable disease
Fig. 3 OS for all patients who received dovitinib plus fulvestrant or placebo plus fulvestrant. NE Not estimable, OS Overall survival
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received placebo) and/or a dose change (57.4% vs 8.0% for
those who received placebo); most patients required a
dose interruption or delay or a dose change owing to
experiencing an AE (70.2% and 53.2%, respectively) (Add-
itional file 2: Table S1).
The most common any-grade AEs in the dovitinib arm,
regardless of cause, were diarrhea (78.7%), nausea (72.3%),
vomiting (57.4%), asthenia (38.8%), and headache (36.2%)
(Table 3). In the placebo arm, diarrhea (32.0%), fatigue
(26.0%), nausea and asthenia (22.0% each), and decreased
appetite (16.0%) were the most common any-grade AEs.
The most common grade 3 AEs (occurring in ≥10% of
patients) in the dovitinib vs placebo arms were hyperten-
sion (21.3% vs 6.0%), diarrhea (14.9% vs 4.0%), alanine
aminotransferase increase (14.9% vs 2.0%), fatigue (12.8%
vs 2.0%), blood alkaline phosphatase increase (12.8% vs
0%), and γ-glutamyltransferase increase (10.6% vs 6.0%).
The median (range) time to the onset of hypertension or
blood pressure increase was 2.9 (0.1–28.1) weeks in the
dovitinib arm and 2.7 (0.1–20.1) weeks in the placebo
arm. In general, grade 4 AEs were infrequent and were
comparable in the two arms, occurring in eight patients
(17.0%) in the dovitinib arm and six patients (12.0%) in
the placebo arm. Serious AEs suspected to be related to
the study drug were reported in six patients (12.8%) in the
dovitinib plus fulvestrant arm and included grade 3
pulmonary embolism, deep vein thrombosis, dehydration,
esophageal varices hemorrhage, pneumonia, and varices
esophageal (2.1% each), and grade 4 pulmonary embolism,
ischemic cerebral infarction, and thrombocytopenia (2.1%
each). In the placebo plus fulvestrant arm, two patients
(4.0%) reported serious AEs suspected to be related to
study drug (grade 4 hypotension [2.0%] and pancreatitis
[2.0%]). The overall incidence of proteinuria and thyroid
Table 3 Most common adverse events (occurring in ≥15% of patients), regardless of study drug relationship
Adverse events occurring in≥ 15%
of patients, by preferred term, n (%)
Dovitinib + fulvestrant (n = 47) Placebo + fulvestrant (n = 50)
Any grade Grade 3a Any grade Grade 3a
Any adverse event 47 (100) 32 (68.1) 47 (94.0) 19 (38.0)
Diarrhea 37 (78.7) 7 (14.9) 16 (32.0) 2 (4.0)
Nausea 34 (72.3) 4 (8.5) 11 (22.0) 1 (2.0)
Vomiting 27 (57.4) 3 (6.4) 4 (8.0) 0
Asthenia 18 (38.8) 4 (8.5) 11 (22.0) 1 (2.0)
Headache 17 (36.2) 2 (4.3) 3 (6.0) 0
Fatigue 16 (34.0) 6 (12.8) 13 (26.0) 1 (2.0)
Rash 16 (34.0) 1 (2.1) 3 (6.0) 0
Alanine aminotransferase increase 15 (31.9) 7 (14.9) 5 (10.0) 1 (2.0)
Dysgeusia 15 (31.9) 0 1 (2.0) 0
Decreased appetite 13 (27.7) 2 (4.3) 8 (16.0) 0
Hypertension 13 (27.7) 10 (21.3) 4 (8.0) 3 (6.0)
Dyspepsia 12 (25.5) 0 0 0
Blood alkaline phosphatase increase 11 (23.4) 6 (12.8) 1 (2.0) 0
Aspartate aminotransferase increase 10 (21.3) 3 (6.4) 4 (8.0) 1 (2.0)
Abdominal pain upper 10 (21.3) 0 3 (6.0) 0
Stomatitis 10 (21.3) 0 2 (4.0) 0
Anemia 9 (19.1) 2 (4.3) 4 (8.0) 1 (2.0)
γ-Glutamyltransferase increase 9 (19.1) 5 (10.6)b 4 (8.0) 3 (6.0)b
Pain in extremity 9 (19.1) 0 3 (6.0) 0
Dry skin 9 (19.1) 0 2 (4.0) 0
Dyspnea 8 (17.0) 1 (2.1) 6 (12.0) 0
Abdominal pain 8 (17.0) 0 5 (10.0) 0
Constipation 8 (17.0) 0 5 (10.0) 0
Hypertriglyceridemia 8 (17.0) 4 (8.5) 1 (2.0) 0
aGrade 4 adverse events occurred in eight patients (17.0%) in the dovitinib + fulvestrant arm and six patients (12.0%) in the placebo + fulvestrant arm, but no
grade 4 adverse events were reported for any of the most common adverse events (occurring in ≥15% of patients), except where noted
bGrade 4 γ-glutamyltransferase increase was reported in three patients (6.4%) in the dovitinib + fulvestrant arm and one patient (2.0%) in the
placebo + fulvestrant arm
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function abnormality was low in the dovitinib arm (two
patients [4.3%] and one patient [2.1%], respectively; all
grade 1/2 AEs) and was not reported in the placebo arm.
More patients discontinued study treatment owing to
AEs in the dovitinib arm than in the placebo arm (38.3%
vs 8.0%). The most frequently reported AEs (occurring in
≥3% of patients) leading to discontinuation were diarrhea
(6.4% vs 0%), alanine aminotransferase increase (4.3% vs
2.0%), aspartate aminotransferase increase (4.3% vs 2.0%),
and rash (4.3% vs 0%) (Additional file 2: Table S2). A total
of four on-treatment deaths were reported (two deaths in
each treatment arm); of the two on-treatment deaths that
occurred in the dovitinib arm, one patient died as a result
of breast cancer progression and one patient died because
of a pulmonary embolism suspected to be related to study
treatment. Overall, 14 patients (29.8%) in the dovitinib
arm and 18 patients (36.0%) in the placebo arm died
during the entire study period (i.e., including the time
beyond the 30-day end of treatment follow-up period).
Discussion
In this randomized, double-blind trial, we evaluated the
safety and efficacy of dovitinib plus fulvestrant compared
with placebo plus fulvestrant in postmenopausal patients
with HR+, HER2− advanced breast cancer that progressed
during or after prior endocrine therapy. The final analysis
was initially planned to occur when 90 PFS events were
recorded in the full population, including ≥50 PFS events
in the FGF-amplified subgroup. However, the study was
terminated early because of slow enrollment in the FGF-
amplified subgroup.
In this study, patients in the FGF pathway–amplified
subgroup who received dovitinib plus fulvestrant had
prolonged median PFS (10.9 vs 5.5 months), with an
estimated 36% risk reduction compared with patients
who received placebo plus fulvestrant. However, a simi-
lar trend in risk reduction with dovitinib plus fulvestrant
treatment (vs placebo plus fulvestrant) was seen in all
patients (32%) and in patients without FGF pathway
amplification (31%). This suggests that dovitinib plus
fulvestrant may have antineoplastic activity regardless of
FGF pathway amplification status in the evaluated
patient population, although the estimated risk reduction
reached statistical significance (as defined in the study
protocol) only in the FGF pathway–amplified cohort.
Furthermore, patients in the dovitinib plus fulvestrant
arm had a higher ORR than patients in the placebo plus
fulvestrant arm (27.7% vs 10.0%), regardless of FGF
pathway amplification status (ORR 20.0% vs 12.5% in
FGF pathway–amplified subgroup; ORR 31.3% vs 8.8%
in FGF pathway–nonamplified subgroup). Nevertheless,
these data should be interpreted cautiously. First, the
small sample size in the FGF pathway–amplified sub-
group contributed to a lower-than-expected number of
PFS events and very large CIs. Second, we cannot
exclude that dovitinib had an effect regardless of FGF
pathway amplification status, given that the number of
events for the full study population was 64 (30 in the
dovitinib arm and 34 in the placebo arm), which was less
than the 90 planned events. One potential explanation
for the activity of dovitinib plus fulvestrant regardless of
FGF pathway amplification status is that, as a multitar-
geted tyrosine kinase inhibitor, dovitinib targeted other
pathways [36], such as signaling through vascular endo-
thelial growth factor receptor or c-Kit, which are overex-
pressed in 10% to 11% and 11% to 17% of breast cancers,
respectively [39, 40].
Safety data were consistent with the known safety
profile of dovitinib [38, 41–44], with no new safety con-
cerns identified with the use of dovitinib in combination
with fulvestrant in patients with HR+, HER2− advanced
breast cancer. The use of FGFR inhibitors in breast can-
cer merits further investigation because other studies of
single-agent FGFR inhibitors showed encouraging results
in patients with breast cancer [38, 45–47]. Resistance to
hormone therapy (i.e., tamoxifen) is potentially mediated
by FGFR signaling through activation of the mitogen-
activated protein kinase (MAPK) and PI3K pathways
[26, 32]. For example, resistance to tamoxifen has been
associated with constitutive activation of MAPK and
the subsequent expression of cyclin D1 in FGFR1-amp-
lified breast cancer cell lines [26]. Similarly, in ER+ cell
lines, activation of FGFR3 reduced sensitivity to
tamoxifen and fulvestrant through activation of MAPK
and PI3K signaling pathways [32]. Furthermore, the
combination of dovitinib and the dual PI3K/mTOR
inhibitor dactolisib (BEZ235) showed strong inhibition
of PI3K pathway activation in vitro and in vivo, as well
as antitumor activity in FGFR-expressing breast cancer
models [48]. Currently, researchers in a phase Ib trial
(ClinicalTrials.gov identifier: NCT01928459) are investi-
gating the pan-FGFR inhibitor BGJ398 in combination
with the selective PI3K inhibitor alpelisib (BYL719) in pa-
tients with solid tumors with FGFR1, FGFR2, and FGFR3
alterations and phosphatidylinositol 4,5-bisphosphate 3-
kinase catalytic subunit α mutations. Thus, further ex-
ploration of the use of FGFR inhibitors in combination
with other agents is warranted.
The present study was terminated early because of slow
accrual. The rates of FGF pathway amplification observed
in this study were lower than previously reported. In the
previous phase II monotherapy study, 10% of the patients
screened who were enrolled in the study had FGFR1
amplification [38], whereas approximately 5% of patients
screened and randomized in this study had FGF pathway
amplifications. In the phase II monotherapy study, many of
the patients were prescreened by the French cooperative
group, which reduced the overall number of patients
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needed to be screened. In addition, the eligibility criteria
allowed more heavily pretreated patients to be enrolled,
which expanded the pool of potential patients. Conducting
clinical trials in molecularly selected patient populations is
challenging, particularly because the screening failure rate
is high with current trial designs [49], accrual can be slow
when the molecular aberration is very rare, and patient
dropout rates [50] and costs [51] can be high. In this study,
accrual of FGF-amplified patients was very slow and
resulted in the early termination of the trial, thereby
confounding interpretation of the results. Several strategies
have been proposed to overcome these challenges. A novel
idea to increase rapid recruitment of patients with rare mo-
lecular markers is to develop molecular screening programs
that screen several genes at a time in a large patient pool,
using next-generation sequencing assays, and then to guide
patients to specific clinical trials on the basis of their
specific biomarkers [52, 53]. One example is the
National Cancer Institute’s Molecular Analysis for
Therapy Choice (NCI MATCH) trial (ClinicalTrials.gov
identifier: NCT02465060); patients are screened for
approximately 200 genes, assigned to a study arm on the
basis of a molecular abnormality, and followed for re-
sponse and PFS [52]. The NCI MATCH study currently
includes 24 arms, in one of which investigators are evalu-
ating the FGFR inhibitor AZD4547 in patients with FGFR
pathway aberrations (FGFR1–FGFR3 amplification, muta-
tion, or translocation). Following progression, patients
may be rescreened and enrolled in a second study arm;
patients may also receive their screening results and de-
cide, together with their doctor, to receive alternative ther-
apy [52]. It remains to be seen whether new trial designs
will have widespread support [50].
Conclusions
In this placebo-controlled study of dovitinib in combination
with fulvestrant in postmenopausal patients with HR+,
HER2− advanced or metastatic breast cancer that pro-
gressed during or after prior endocrine therapy did not
identify any new safety findings. Dovitinib in combination
with fulvestrant showed promising clinical activity in the
FGF pathway–amplified subgroup. However, the reported
data should be interpreted with caution, given that fewer
PFS events than expected occurred in the FGF pathway–
amplified patients and that we cannot exclude an effect of
dovitinib regardless of FGR pathway amplification status,
owing to the smaller-than-expected sample size.
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